Showing results (1-10 of 58) with videos related to
Sort By:
Pageof 6
Hypertension Research : Official Journal of the Japanese Society of Hypertension|February 25, 2026
Reduction of interstitial fluid retention by combination therapy with dapagliflozin, an SGLT2 inhibitor, and conventional diuretics: comment on a post-hoc analysis of the DAPA-BODY trialTakuya TomaruJournal of Diabetes and Its Complications|September 5, 2020
Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysisShintaro Sakurai, Teruo Jojima, Toshie Iijima, et al.The Journal of Biological Chemistry|January 8, 2009
Adipocyte-specific expression of murine resistin is mediated by synergism between peroxisome proliferator-activated receptor gamma and CCAAT/enhancer-binding proteinsTakuya Tomaru, David J Steger, Martina I Lefterova, et al.Diabetes|June 4, 2009
Endoplasmic reticulum stress regulates adipocyte resistin expressionMartina I Lefterova, Shannon E Mullican, Takuya Tomaru, et al.Endocrinology|October 22, 2005
Isolation and characterization of a transcriptional cofactor and its novel isoform that bind the deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gammaTakuya Tomaru, Teturou Satoh, Satoshi Yoshino, et al.Endocrine Journal|May 13, 2021
Symptomatic hypocalcemia after treatment for hyperthyroidism in a woman with chromosome 22q11.2 deletion syndrome complicated by Graves' disease: longitudinal changes in the number of subsets of CD4 and CD8 lymphocytes after thyroidectomyToshie Iijima, Teruo Jojima, Soichiro Hosonuma, et al.Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|May 21, 2021
Serum high-molecular-weight adiponectin and response to dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver diseaseYoshimasa Aso, Masaaki Sagara, Takafumi Niitani, et al.Expert Opinion on Pharmacotherapy|May 29, 2024
Empagliflozin increases plasma levels of citrulline, histidine, and α-aminobutyric acid in patients with type 2 diabetes: effects of a sodium-glucose co-transporter 2 inhibitor on the plasma amino acid profileTeruo Jojima, Shintaro Sakurai, Haruka Kishi, et al.The American Journal of the Medical Sciences|June 17, 2020
Teneligliptin, a DPP-4 Inhibitor, Decreases Plasma Levels of Inflammatory Chemokines During a Standard Meal Test in Patients With Type 2 DiabetesYoshimasa Aso, Masato Kase, Masaaki Sagara, et al.Molecular Endocrinology (Baltimore, Md.)|November 30, 2012
A novel adipose-specific gene deletion model demonstrates potential pitfalls of existing methodsShannon E Mullican, Takuya Tomaru, Christine A Gaddis, et al.Pageof 6